IRBESARTAN,

ApprovedSmall molecule

AAssistance Publique - Hôpitaux de Paris

IRBESARTAN, is one of 57 small molecule programs targeting Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

Acute Kidney InjuryActive, not recruiting

HypertensionApproved

Active, not recruiting

Acute Kidney InjuryPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

IRBESARTAN,

AAssistance Publique - Hôpitaux de Paris

Approved

1 2

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 3

Winrevair

Merck & Co.

Preclinical

—4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 5

Avastin

BBio-Thera Solutions

Preclinical

1 6

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—8

Vivarin

HHikma Pharmaceuticals LLC

Salbutamol

1 10

Sodium Nitroprusside

WWatson Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Kidney Injury1 trial

Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU.

Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05272878·508 enrolled

Hypertension1 trial

PHARES Study: Management of Resistant Hypertension

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00224549·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IRBESARTAN,. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IRBESARTAN, compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IRBESARTAN,. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAssistance Publique - Hôpitaux de Paris

IRBESARTAN,

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Kidney Injury1 trial

Hypertension1 trial

References

Drug Info

Quick Facts

Related News